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Methods
Methods

Background
Chronic rhinosinusitis (CRS) is common and incurs a
significant human and economic cost.
CRS is defined as: symptomatic inflammation of the
paranasal sinuses and nasal cavities lasting longer than 12
weeks.
Treatments include:
Medical therapy:
• saline irrigation
• nasal corticosteroids
• oral antibiotics
• biologics
Procedures:
• balloon ostial dilation
• functional endoscopic sinus surgery (FESS)

In Louisiana Medicaid’s expenditures for calendar year 2019,
there were 1,102 distinct recipients of sinus surgery (either
balloon ostial dilation or FESS) for a total of $2,382,366 in
professional services expenditures.

Policy Recommendation

Evidence and guidelines for this review were collected with relevant search
terms utilized from studies in peer-reviewed journals, including:
• American Journal of Otolaryngology – Head and Neck Surgery
• American Journal of Rhinology
• International Forum of Allergy and Rhinology
• Cochrane Library
• Journal of the American Medical Association
Policy Design Process:
Analysis of Louisiana
Medicaid claims data to
determine if there is high
utilization/high cost
associated with nasal
endoscopy.

Evidence search for
literature that is relevant to
the use of nasal endoscopy
for the treatment of chronic
rhinosinusitis.

Policy Brief comparing
policies for coverage of
chronic rhinosinusitis that
currently exist with new
recommendations based
based on available evidence.

Evidence review
summarizing the evidence
for the use of nasal
endoscopy in the treatment
of chronic rhinosinusitis.

Results
Objective

1. Review the evidence of efficacy and safety for the
treatments for CRS and review current policies
among insurance plans serving Louisiana’s Medicaid
beneficiaries.
2. Develop policy recommendations for the Louisiana
Medicaid program regarding the treatment of CRS.

- High-quality evidence for the use of nasal irrigation and nasal corticosteroids
for the relief of CRS symptoms
- Evidence of the efficacy and safety of oral antibiotics, outside of the treatment
of a diagnosed bacterial infection is lacking
- Evidence about the comparative effectiveness of medications or combination
medication regimens is lacking
- Endoscopic sinus surgery should be reserved for those patients refractory to
medical management; evidence indicates that those with more symptom
burden and/or lower quality of life at baseline may be more likely to benefit
- There is no evidence on the efficacy of balloon ostial dilation versus FESS

Balloon ostial dilation and FESS are considered medically
necessary for the treatment of CRS when all of the following
criteria are met:

1. Uncomplicated chronic rhinosinusitis limited to the paranasal
sinuses without the involvement of adjacent neurological, soft
tissue, or bony structures that has persisted for at least 12
weeks with at least two of the following sinonasal symptoms:
a. Facial pain/pressure;
b. Hyposmia/anosmia;
c. Nasal obstruction;
d. Mucopurulent nasal discharge; and
2. Sinonasal symptoms that are persistent after maximal
medical therapy has been attempted, as defined by all of the
following:
a. Saline nasal irrigation for at least 6 weeks;
b. Nasal corticosteroids for at least 6 weeks;
c. Approved biologics for at least 6 weeks;
d. Antibiotic therapy when an acute bacterial infection is
suspected;
e.Treatment of concomitant allergic rhinitis, if present; and
3. Objective evidence of sinonasal inflammation as determined
by one of the following:
a. Nasal endoscopy; or
b. Computed tomography.
This policy recommendation was adopted into the Louisiana
Medicaid Professional Services Provider Manual on 2/10/22.
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